SNCA Protein

Catalog No. ABIN7198176

This Recombinant SNCA protein is produced in Escherichia coli (E. coli).

Quick Overview for SNCA Protein (ABIN7198176)

Target: SNCA (Synuclein, alpha (SNCA))

Protein Type: Recombinant

Origin: Human

Source: Escherichia coli (E. coli)

Purity: > 97 % as determined by reducing SDS-PAGE.

Product Details

Purpose: Recombinant Human Alpha-Synuclein/SNCA Protein

Sequence: Met 1-Ala 140

Characteristics: A DNA sequence encoding the mature form of human SNCA isoform 1 (P37840-1) (Met 1-Ala 140) was expressed and purified.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Target Details

Target: SNCA (Synuclein, alpha (SNCA))

Alternative Name: Alpha-Synuclein/SNCA

Background:

Background: Alpha-Synuclein (alpha-Syn), also known as NACP or SNCA, exists as at least two structural isoforms: one is helix-rich, membrane-bound form that both the N- and C-terminal regions of alpha-synuclein are tightly associated with membranes and the other is disordered, cytosolic form. Synuclein is found predominantly in the presynaptic termini, in both free or membrane-bound forms. SNCA is extensively localized in nucleus of neurons. It has been shown that alpha-Synuclein was highly expressed in the mitochondria in olfactory bulb, hippocampus, striatum, and thalamus, where the cytosolic alpha-Synuclein was also rich. Normally the unstructured soluble type of alpha-synuclein can aggregate to form insoluble fibrils in pathological conditions characterized by Lewy bodies, such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. SNCA abnormality and mitochondrial deficiency are two major changes in the brain of patients with Parkinson's disease (PD). In addition, alpha-synuclein is an abundant component of Lewy bodies in sporadic Parkinson's disease and diffuse Lewy body disease.

Synonym: Vascular endothelial growth factor receptor 2, KDR, VEGFR-2, Fetal liver kinase 1, FLK-1, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1,CD309,Flk-1,FLK1,VEGFR,VEGFR2

Molecular Weight: 14.5 kDa

Pathways: Synaptic Membrane, Regulation of G-Protein Coupled Receptor Protein Signaling, Positive Regulation of Endopeptidase Activity, Regulation of Carbohydrate Metabolic Process, Platelet-derived growth Factor Receptor Signaling, Negative Regulation of Transporter Activity, Regulation of long-term Neuronal Synaptic Plasticity